Patients receiving Defitelio should be carefully monitored for bleeding and hypersensitivity reactions.

Safety Precautions

Defitelio carries important safety warnings that clinicians must observe. First, bleeding risk is heightened, and patients should be monitored for any signs of hemorrhage. If significant bleeding occurs, treatment with Defitelio should be withheld or discontinued. Additionally, hypersensitivity reactions are possible, and if severe or life-threatening allergic reactions occur, Defitelio should be discontinued, and appropriate medical management should be initiated. Regular assessment for these reactions is crucial during the treatment course, especially given the critical condition of the patient population.